These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32239791)

  • 1. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
    Pizzatti L; Mugheddu C; Sanna S; Atzori L; Rongioletti F
    Dermatol Ther; 2020 May; 33(3):e13348. PubMed ID: 32239791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
    Liu LC; Jin XH; Sun C; Xia JX
    Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis.
    Ikuma D; Oguro M; Hoshino J; Mizuno H; Sekine A; Kawada M; Hiramatsu R; Sumida K; Hasegawa E; Hayami N; Yamanouchi M; Suwabe T; Sawa N; Takaichi K; Ubara Y
    CEN Case Rep; 2020 Feb; 9(1):55-58. PubMed ID: 31654299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review.
    Zhao Z; Zhang X; Wang R; Wang Y; Gong L; Li C
    Dermatol Ther; 2022 Sep; 35(9):e15684. PubMed ID: 35789520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
    Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
    J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
    Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB; Blauvelt A; Prinz JC; Papanastasiou P; Pathan R; Nyirady J; Fox T; Papavassilis C
    J Drugs Dermatol; 2016 Oct; 15(10):1226-1234. PubMed ID: 27741340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis.
    Galluzzo M; D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2020 Feb; 20(2):173-182. PubMed ID: 31880166
    [No Abstract]   [Full Text] [Related]  

  • 16. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.
    Ohtsuki M; Morita A; Igarashi A; Imafuku S; Tada Y; Fujita H; Fujishige A; Yamaguchi M; Teshima R; Tani Y; Nakagawa H
    J Dermatol; 2017 Oct; 44(10):1105-1111. PubMed ID: 28543617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
    Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
    Mrowietz U; Leonardi CL; Girolomoni G; Toth D; Morita A; Balki SA; Szepietowski JC; Regnault P; Thurston H; Papavassilis C;
    J Am Acad Dermatol; 2015 Jul; 73(1):27-36.e1. PubMed ID: 25982539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.